Project Grant R01MH141038
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $100,228 on November 26, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the role of ketamine in modulating intrinsic neural timescales in treatment-resistant depression. The project hypothesizes that disruptions in excitation/inhibition balance within canonical neural microcircuits underlie cognitive deficits in treatment-resistant depression, and that ketamine normalizes...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $462,000 on August 14, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop a novel spatial transcriptomics platform and investigate RNA-binding protein function in human neurons as it relates to schizophrenia risk. The award funds two primary aims. The first develops a spatial RNA-protein interactome MERFISH (SPRIM) platform to visualize endogenous RNA-protein interactions at...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $827,879 on March 25, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate ghrelin receptor and striosomal interactions in stress-induced decision-making. The award supports basic neuroscience research examining how chronic stress exposure alters decision-making through interactions between neural circuits and endocrine mechanisms. The research uses mouse models to explore how...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $701,763 on April 24, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the role of the ventral CA1 hippocampal subregion in valence-associated social memories and emotional memory processing. The five-year project, which runs through January 31, 2031, will uncover the neural circuits mediating positive and negative social memories, identify hippocampal cell types supporting...
- The National Institute of Mental Health awarded Albert Einstein College of Medicine $149,190 on September 11, 2026, under the Mental Health Research Grants program (CFDA 93.242) to characterize the effects of the kynurenine pathway on blood-brain barrier disruption and CD14+CD16+ monocyte function in people with HIV and comorbid depression. The project investigates neurobiological mechanisms linking HIV-associated depression to activation of the kynurenine pathway, a metabolic process implicated...
- The National Institute of Mental Health awarded $1.579 million to the Research Foundation For Mental Hygiene, Inc., operating as the New York State Psychiatric Institute, on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to fund basic neuroscience research into the circuit mechanisms by which early-life adversity produces sustained reward deficits. The research examines how childhood trauma—including abuse, neglect, and chronic stress—alters neural circuits governing...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $169,701 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct multiomic and spatial profiling of hippocampal development and subfield specification. The research deploys single-nucleus RNA sequencing, single-nucleus ATAC sequencing, and spatial sequencing on human fetal hippocampal and neocortical tissue (gestational weeks 16–24) and human induced pluripotent stem...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $861,666 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a prospective pregnancy cohort study examining the combined role of endogenous and exogenous oxytocin in postpartum depression and anxiety risk. The study will recruit participants during the second or third trimester of pregnancy and follow them through three months postpartum to measure depression and...
- The National Institute of Mental Health awarded The Research Foundation for The State University of New York $437,125 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a preliminary positron emission tomography study quantifying the mechanism of transcranial magnetic stimulation in depression. The recipient, operating as Stony Brook University, will investigate the relationship between repetitive transcranial magnetic stimulation (rTMS)—an FDA-approved...
- The National Institute of Mental Health awarded Yale University $711,168 under Mental Health Research Grants (CFDA 93.242) on September 1, 2026, to identify circuit mechanisms by which insular cortex immune-responsive neurons alter behavior during peripheral inflammation. The project uses mouse models of type 2 and type 3 inflammation combined with single-cell transcriptomics, electrophysiology, and chemogenetics to determine whether insular cortex immune-responsive neurons are heterogeneous and...
The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $839,815 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a clinical and translational research project investigating neuroimmune mechanisms of depression and anhedonia. The project tests the hypothesis that heightened peripheral immune function and increased blood-brain barrier permeability contribute to major depressive disorder and anhedonia severity. Work is organized across three study aims: characterization of peripheral myeloid cell biology in association with depression and anhedonia; characterization of blood-brain barrier permeability and reward circuit functional connectivity; and characterization of temporal dynamics of immune, blood-brain barrier, and reward circuit features over a three-month follow-up period. The research will enroll 150 medically healthy adults aged 18 to 55 years, including 100 individuals with major depressive disorder and 50 unaffected volunteers. All participants will undergo detailed clinical and behavioral assessment, blood collection for myeloid cell characterization including transcriptional and proteomic profiling, and neuroimaging with dynamic contrast enhancement and diffusion-prepared arterial techniques. Performance occurs at New York, NY 10029. The period of performance extends from August 1, 2026, to April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $839.8k | 7/31/26 |